NCT03252431 2023-07-03
Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
EVIVE Biotechnology
Phase 3 Completed
Clinical Trials
11 trialsNCT02643420 2022-03-02
ADVANCE
Spectrum Pharmaceuticals, Inc
Phase 3 Completed
NCT02953340 2022-03-02
SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide
Spectrum Pharmaceuticals, Inc
Phase 3 Completed
NCT02872103 2021-05-05
Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
EVIVE Biotechnology
Phase 3 Completed
NCT01371656 2020-12-07
Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation
Children's Oncology Group
Phase 3 Completed
NCT00911170 2017-12-29
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
Amgen
Phase 3 Completed
NCT01516736 2017-08-30
PROTECT2
Sandoz
Phase 3 Completed
NCT01735175 2017-08-07
PROTECT-1
Sandoz
Phase 3 Completed
NCT02104830 2016-10-24
Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Breast Cancer Patients
Biocad
Phase 3 Completed
NCT01519700 2015-05-06
PIONEER
Sandoz
Phase 3 Completed
NCT00529282 2012-08-01
A Study of Ceftobiprole in Patients With Fever and Neutropenia.
Basilea Pharmaceutica
Phase 3 Terminated